Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This page aggregates official press releases and verified news about the company’s clinical developments, research breakthroughs, and strategic partnerships.
Investors and industry professionals will find timely updates on ALGS’ pipeline candidates including oral capsid assembly modulators targeting viral suppression in CHB and THR-β agonists addressing liver fat reduction in MASH. The curated news collection provides essential context for understanding clinical trial progress, regulatory milestones, and scientific advancements.
Key content categories include updates on: Phase 1-3 clinical trials, collaborative research initiatives, regulatory communications, and therapeutic mechanism insights. All information is sourced from official company disclosures and reputable industry publications.
Bookmark this page for structured access to ALGS’ evolving scientific narrative. Check regularly for developments in oligonucleotide-based therapies and small molecule candidates progressing through clinical evaluation.
Aligos Therapeutics (Nasdaq: ALGS) announced inducement equity awards granted by its Compensation Committee on Nov 11, 2025 to newly hired employees. An aggregate of 23,600 non-qualified stock options were granted under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing stock price on the grant date and vest over four years with 25% vesting after one year and the remainder monthly thereafter, subject to continued employment.
Aligos Therapeutics (NASDAQ: ALGS) presented positive clinical and preclinical data for pevifoscorvir sodium (ALG-000184) and its active moiety ALG-001075 at The Liver Meeting® 2025 (Nov 7–11, 2025).
Key clinical results: in Phase 1 monotherapy, 300 mg daily pevifoscorvir produced rapid, durable HBV DNA suppression with 100% (10/10) HBeAg+ subjects
Aligos Therapeutics (Nasdaq: ALGS) reported Q3 2025 business progress and financials on Nov 6, 2025. Pevifoscorvir sodium Phase 2 B-SUPREME began dosing (first patient Aug 2025) in ~200 untreated chronic HBV subjects across the U.S., China, Hong Kong, and Canada; interim readouts are projected in 1H and 2H 2026 with topline in 2027. Phase 1 post-treatment data (96 weeks dosing) will be presented at The Liver Meeting 2025.
Cash plus investments were $99.1M at Sept 30, 2025, funding planned operations into Q3 2026. Q3 net loss was $31.5M (loss per share $(3.04)); R&D expense was $23.9M. Company is evaluating funding options including potential out-licensing for continued development.
Aligos Therapeutics (Nasdaq: ALGS) announced management will present at two investor conferences in late 2025: a Jefferies London Healthcare Conference fireside chat on November 17, 2025 at 3:00 PM GMT and a Piper Sandler 37th Annual Healthcare Conference fireside chat on December 3, 2025 at 2:00 PM ET.
Both presentations will premiere at the listed times and are accessible via the Presentation & Events section on Aligos’ Investors page at www.aligos.com. A replay of each webcast will be available for at least 30 days following the presentation.
Aligos Therapeutics (Nasdaq: ALGS) will release its third quarter 2025 financial results on Thursday, November 6, 2025 before the U.S. market opens. The company is a clinical-stage biotech focused on therapies for liver and viral diseases. Investors can expect a routine pre-market earnings release and any accompanying commentary or webcast details to be announced separately.
Aligos Therapeutics (Nasdaq: ALGS) announced on Oct 17, 2025 that its Compensation Committee granted non-qualified stock options totaling 27,400 shares as inducement awards to newly hired employees, effective Oct 15, 2025.
The awards were made under the companys 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing price on the Grant Date and vest over four years with 25% vesting at the first anniversary and the remainder vesting in equal monthly installments, subject to continued employment.
Aligos Therapeutics (Nasdaq: ALGS) announced that the USAN Council has adopted pevifoscorvir sodium as the nonproprietary (generic) name for ALG-000184, an investigational therapy for chronic hepatitis B virus (HBV) infection. The name is intended to provide consistent identification and support international recognition and transparency.
The company said the name, shortened to “pevy,” is the first generic name assigned to a compound at Aligos and comes as the program advances through the ongoing Phase 2 B-Supreme study. The announcement highlights a regulatory-naming milestone rather than clinical readouts or approvals.
Aligos Therapeutics (Nasdaq: ALGS) will present at the H.C. Wainwright Liver Disease Conference on October 21–22, 2025. Members of management will deliver a company presentation covering recent clinical and corporate developments.
Investors can watch a live webcast via the Presentation & Events section on Aligos’ investor website at www.aligos.com. A replay will be available for at least 30 days after the presentation.
Aligos Therapeutics (Nasdaq: ALGS) announced eight abstracts accepted for The Liver Meeting® 2025 (Nov 7–11, 2025), including one oral presentation on 96-week and post-treatment follow-up data from the Phase 1 monotherapy study of ALG-000184, a capsid assembly modulator for chronic hepatitis B (HBV).
Highlights include an oral session on Nov 9, 2025 reporting that once-daily 300 mg ALG-000184 "demonstrates potent suppression of HBV DNA," a poster reporting sustained reduction of HBV antigen levels during an 8-week follow-up after 96 weeks of treatment, and multiple preclinical posters on CAM compounds and siRNA candidates for liver disease.
Aligos Therapeutics (Nasdaq: ALGS) announced six preclinical presentations at the 2025 International HBV Meeting in Berlin, including three oral presentations. The presentations showcase the company's research in liver and viral diseases, particularly focusing on ALG-000184 and a new antisense oligonucleotide (ASO) approach for hepatitis delta virus (HDV) treatment.
Key highlights include the first presentation of ALG-000184's direct effects in reducing HBV cccDNA in preclinical settings, supporting clinical observations of HBV antigen reductions in patients. Additionally, the company is expanding its pipeline with an ASO program for HDV treatment, targeting viral genome destruction as a potential cure strategy for HDV coinfection, which typically leads to more rapid disease progression.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
